Januvia Gets Fast Start; Uptake Seen In Variety Of Diabetes Settings, Merck Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company reports sales of $42 million for sitagliptin during the DPP-4 inhibitor's first quarter on the market.
You may also be interested in...
Avandia Not Losing Market Share To Januvia, GSK Reports
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.
Avandia Not Losing Market Share To Januvia, GSK Reports
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.
DPP IV Inhibitor Januvia First Out Of The Gate
Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.